Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid and Rituximab in IgG4-Related Disease
NCT02705638Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide in IgG4-related disease (IgG4-RD), sponsored by Mayo Clinic. Primary endpoint: Number of subjects in remission for Immunoglobulin G subclass 4 Related Disease at 24 months. Started Apr 2016; status: completed.
02
Drugs
lenalidomide
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT02705638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705638.